Parexel (PRXL) Misses Q3 EPS by 1c, Lowers FY Guidance

Parexel (NASDAQ: PRXL) reported Q3 EPS of $0.89, $0.01 worse than the analyst estimate of $0.90. Revenue for the quarter came in at $611.4 million versus the consensus estimate of $523.22 million.

GUIDANCE:

Parexel sees Q4 2016 EPS of $0.89-$0.97, versus the consensus of $1.00. Parexel sees Q4 2016 revenue of $528-538 million, versus the consensus of $545.92 million.

Parexel sees FY2016 EPS of $3.38-$3.46, versus prior guidance of $3.40-$3.58 and the consensus of $3.54. Parexel sees FY2016 revenue of $2.085-2.095 million, versus the consensus of $2.11 million.

For earnings history and earnings-related data on Parexel (PRXL) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Movano (MOVE) Misses Q2 EPS by 195c
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c